These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 22842506)

  • 41. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 44. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
    Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
    Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation.
    Yu HC; Tsai YF; Chen MC; Yeh CH
    Int J Stroke; 2012 Feb; 7(2):112-7. PubMed ID: 22103748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
    Tomita F; Kohya T; Kitabatake A
    Nihon Rinsho; 2000 Jun; 58(6):1326-34. PubMed ID: 10879060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
    Rockson SG; Albers GW
    J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
    Masbah N; Macleod MJ
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing the guard in long-term anticoagulation: clinical and economic implications.
    Lepor NE
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S22-9. PubMed ID: 15619612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M; Goette A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective costing of warfarin.
    Walsh C; Murphy A; Kirby A; Vaughan C
    Ir Med J; 2014 May; 107(5):133-5. PubMed ID: 24908854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Left Atrial Enlargement and Anticoagulation Status in Patients with Acute Ischemic Stroke and Atrial Fibrillation.
    Dakay K; Chang AD; Hemendinger M; Cutting S; McTaggart RA; Jayaraman MV; Chu A; Panda N; Song C; Merkler A; Gialdini G; Kummer B; Lerario MP; Kamel H; Elkind MSV; Furie KL; Yaghi S
    J Stroke Cerebrovasc Dis; 2018 Jan; 27(1):192-197. PubMed ID: 28918087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atrial fibrillation.
    Lip GY; Tse HF; Lane DA
    Lancet; 2012 Feb; 379(9816):648-61. PubMed ID: 22166900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.
    Kasmeridis C; Apostolakis S; Ehlers L; Rasmussen LH; Boriani G; Lip GY
    Pharmacoeconomics; 2013 Nov; 31(11):971-80. PubMed ID: 24085625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK.
    Das M; Panter L; Wynn GJ; Taylor RM; Connor N; Mills JD; Kirchhof P; Gupta D
    BMJ Open; 2015 Dec; 5(12):e009267. PubMed ID: 26656021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Warfarin in non-valvular atrial fibrillation.
    Dalby AJ; Wessels P; Opie LH
    S Afr Med J; 2013 Oct; 103(12):901-4. PubMed ID: 24300625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    Am J Cardiol; 2015 Apr; 115(8):1095-101. PubMed ID: 25724781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Underuse of anticoagulation in patients with atrial fibrillation.
    Vallakati A; Lewis WR
    Postgrad Med; 2016; 128(2):191-200. PubMed ID: 26666288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Recent development of anticoagulation in stroke prevention for atrial fibrillation].
    Suzuki S; Yamashita T
    Nihon Rinsho; 2014 Jul; 72(7):1282-6. PubMed ID: 25163322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants.
    Leminen A; Pyykönen M; Tynkkynen J; Tykkyläinen M; Laatikainen T
    BMC Health Serv Res; 2019 Nov; 19(1):901. PubMed ID: 31775847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.